

FROM MONOGENIC SYNDROMES TO POLYGENIC RISK AND EPIGENETIC PROGRAMMING: THE GENETIC ARCHITECTURE OF CHILDHOOD OBESITY AND ITS IMPLICATIONS FOR PERSONALIZED THERAPY

Magomed Sultanovich Zakrailov^{1*}, Magomed Said Sultanovich Nazhmudinov¹, Magomed-Salyakh Khuseynovich Varayev¹, Kristina Vitalievna Antokhova², Alina Magomedovna Tkhabisimova², Asya Vadimovna Simonova², Valeria Vladimirovna Igolkina³, Anna Gennadyevna Vakulina³

¹ Clinical Institute of Children's Health, Saratov State Medical University named after V.I. Razumovsky, Saratov, Russia

² Faculty of Pediatrics, Rostov State Medical University, Rostov-on-Don, Russia

³ Faculty of Medicine, Institute of Clinical Medicine, Saratov State Medical University named after V.I. Razumovsky, Saratov, Russia

*Corresponding author: Magomed Sultanovich Zakrailov, e-mail: Zakrailov03@bk.ru

ABSTRACT

Childhood obesity is a heritable trait, with twin studies estimating BMI heritability at 40–70%, yet loci identified through genome-wide association studies still explain only a fraction of this variance. This review synthesizes evidence on the genetic architecture of pediatric obesity across three mechanistic tiers. First, monogenic forms arising from mutations in the leptin–melanocortin pathway (LEP, LEPR, POMC, PCSK1, MC4R) produce early, intense hyperphagia and severe obesity amenable to targeted pharmacotherapy, including metreleptin and the melanocortin-4 receptor agonist setmelanotide. Second, the polygenic architecture uncovered by genome-wide association studies now spans more than one hundred loci, including FTO, MC4R, and ADCY3, distilled into polygenic risk scores that, drawing on data from over five million individuals across ancestries, explain up to 17.6% of BMI variance in European-ancestry adults and predict accelerated weight gain from as early as 2.5 years of age in the ALSPAC cohort. Third, epigenetic programming in utero, evidenced most clearly by cord-blood methylation studies from the Boston Birth Cohort, links maternal adiposity and inflammation to offspring obesity risk through specific CpG sites, with mediated proportions of the maternal-to-child obesity association reaching 25%. We integrate longitudinal cohort data from ALSPAC and the Boston Birth Cohort to quantify how these tiers jointly shape weight trajectories from infancy through adolescence, and discuss pharmacogenetic predictors of treatment response. We conclude that genetic evaluation is becoming a practical instrument for early risk stratification and mechanism-based treatment selection in pediatric obesity, provided polygenic tools are validated and re-derived across ancestries.

KEYWORDS: childhood obesity; monogenic obesity; leptin-melanocortin pathway; genome-wide association study; polygenic risk score; DNA methylation

1. INTRODUCTION

Childhood obesity is increasingly recognized as a heterogeneous condition with distinct underlying causes. Pediatric obesity ranges from single-gene disorders with defined molecular lesions to the extreme of a population-wide distribution of genetic liability. Distinguishing between them matters clinically, as the two ends of the spectrum require entirely different management.

The scale of the epidemic underscores the clinical urgency of this question. Global projections built on data from 191 countries estimate that childhood overweight and obesity will reach roughly 30% by 2030, with higher figures in middle- and high-income countries and the Western Pacific region [1]. The widely cited WHO estimate of 250 million affected children and adolescents by 2030 frames obesity as one of the decade's defining pediatric health problems [2]. Modelling extending to 2050 suggests obesity, as distinct from overweight, will keep rising even as overweight prevalence stabilizes – implying a growing burden at the more severe end of the distribution, where genetic contributions are strongest [3].

Heritability estimates from twin studies place the genetic contribution to BMI at 40–70% [4,5], rising rather than falling at higher BMI values [4]. Genome-wide association studies (GWAS) have identified more than one hundred loci associated with BMI, yet these variants collectively explain only a modest slice of the estimated heritability – the missing heritability problem that has shaped obesity genetics research for over a decade [4]. Part of the explanation, as this review argues, is that obesity genetics is not one field but three, operating on different timescales and through different mechanisms.

The first tier comprises rare, high-penetrance mutations in the leptin-melanocortin pathway, producing a distinct phenotype: normal birth weight followed by rapid weight gain driven by hyperphagia that begins in infancy and cannot be reasoned away by parenting advice. The second tier is the common-variant, polygenic background that shapes obesity risk across the population and increasingly can be summarized in a single risk score. The third

operates before birth: maternal metabolic status and inflammation appear to leave a molecular signature, detectable in cord blood as altered DNA methylation, that partially explains why children of mothers with obesity are themselves more likely to develop obesity, independent of inherited sequence variants. These tiers are not mutually exclusive; a child with a heterozygous MC4R variant, for example, carries a polygenic background that modulates how severely that variant manifests [6]. This review lays out what is known about each tier, summarizes what longitudinal cohorts (ALSPAC, Generation R, the Boston Birth Cohort, and others) have contributed, and translates the findings into a framework for bedside use: when to test, what to test for, and which therapies exist for which genetic diagnosis.

2. Monogenic Obesity: The Leptin-Melanocortin Pathway

2.1 A single circuit, several points of failure

The leptin-melanocortin pathway is, in essence, a relay: adipose tissue signals its energy stores to the hypothalamus via leptin; leptin receptor (LEPR)-bearing neurons in the arcuate nucleus respond by processing proopiomelanocortin (POMC) into alpha-melanocyte-stimulating hormone (α -MSH), a step that requires the enzyme PCSK1; α -MSH then activates the melanocortin-4 receptor (MC4R) on downstream neurons to suppress appetite. A mutation anywhere along this relay produces a strikingly similar clinical picture: normal weight at birth, then intense, unrelenting hunger and rapid weight gain within months. What differs between these disorders is not the hunger itself but the accompanying endocrine and developmental findings, which is precisely what allows clinicians to distinguish one from another without waiting for a genetic result.

2.2 Leptin and its receptor

Congenital leptin deficiency was the first of these disorders described, in two severely obese, consanguineous cousins of Pakistani origin carrying a homozygous frameshift mutation in the leptin gene [7]. Since that 1997 report, dozens of additional LEP mutations have been catalogued, again concentrated in consanguineous populations, and a single cohort of 145 affected Pakistani children with LEP, LEPR, or MC4R deficiency documented mortality of 26% and 9% for LEP and LEPR deficiency respectively, chiefly from pulmonary and gastrointestinal infections, confirming this is a distinct, life-threatening endocrine disease rather than a benign variant of common obesity [8]. A structurally related but functionally distinct disorder, biallelic mutation of the leptin receptor, produces a similar phenotype but with normal or elevated circulating leptin, since the hormone itself is intact but cannot signal [9].

The therapeutic contrast is instructive. Leptin deficiency responds to metreleptin: the original report described marked reductions in food intake and body fat [10], reproduced in later series, including two Colombian sisters whose BMI fell from the 50s–60s to the 30s–40s over one year, with reversal of hypogonadotropic hypogonadism [11]. Leptin receptor deficiency, in contrast, does not respond to metreleptin, because the defect lies downstream of the ligand; these patients instead respond to the melanocortin-4 receptor agonist setmelanotide, which bypasses the defective receptor entirely by acting further down the pathway [12].

2.3 POMC and PCSK1 deficiency

Loss-of-function mutations in POMC prevent synthesis of both ACTH and α -MSH from a single precursor, producing a distinctive triad: severe early-onset obesity, adrenal insufficiency, and red hair with pale skin, first described by Krude and colleagues in two infants presenting with neonatal hypoglycemia and jaundice [13]. The pigmentary finding is not universal – several subsequently reported cases lack the classic red hair, so its absence should not exclude the diagnosis [14]. Clinically, adrenal insufficiency usually declares itself first, in the neonatal period, well before obesity is apparent; because unrecognized adrenal crisis is fatal, POMC deficiency is one of the few genetic obesity syndromes where diagnosis is a genuine emergency. This sequencing also governs treatment: adrenal insufficiency must be adequately corrected with glucocorticoid replacement before setmelanotide is started, since regulatory guidance requires adrenal function to be evaluated and, where impaired, treated first – untreated adrenal insufficiency is not a contraindication to eventual therapy, but it must be addressed before, not alongside, initiation of melanocortin agonism [15].

PCSK1 encodes the prohormone convertase that cleaves POMC and other prohormones, including proinsulin and proglucagon-derived peptides. Its deficiency produces a broader endocrinopathy: obesity with ACTH deficiency, hypoglycemia, malabsorptive diarrhea from impaired intestinal prohormone processing, and hypogonadotropic hypogonadism [16,17]. As with LEPR deficiency, both POMC and PCSK1 deficiency are amenable to setmelanotide once any coexisting adrenal insufficiency is controlled [12,15].

2.4 MC4R deficiency

Heterozygous loss-of-function mutations in MC4R are, by a wide margin, the most frequently identified monogenic cause of severe obesity, accounting for an estimated 1.5–5.8% of children with severe, early-onset obesity depending on population and variant-classification stringency [18,19]. In the largest assembled cohort to date – more than 7,700 individuals screened for pathogenic variants – prevalence was 4.1%, and carriers showed lower LDL-cholesterol and triglyceride levels than BMI-matched controls, highlighting the pleiotropic effects of MC4R beyond energy balance [20]. Inheritance is autosomal dominant, penetrance incomplete, and the phenotype in heterozygous carriers is intermediate: hyperphagia is present but typically milder than in leptin or LEPR deficiency, attenuating somewhat with age [18]. Mechanistically, MC4R and the adenylyl cyclase ADCY3 colocalize at the primary cilia of a subset of hypothalamic neurons; mutations impairing this ciliary localization increase body weight in experimental models, linking this gene to the ciliopathy biology discussed below [21].

Unlike LEPR, POMC, and PCSK1 deficiency, MC4R deficiency is not an approved setmelanotide indication. A 28-day phase 1b trial found weight loss in heterozygous carriers was substantially smaller than with upstream defects; later work suggests response depends on residual signalling capacity, but use remains investigational [12,22].

2.5 Syndromic, ciliopathy-related obesity

A second family of monogenic obesity disorders arises from dysfunction of the primary cilium, an organelle in which MC4R and ADCY3 both function. Bardet-Biedl syndrome (BBS), caused by variants in more than twenty-five BBSome trafficking-complex genes, combines early-onset obesity and hyperphagia with retinal dystrophy, polydactyly, renal anomalies, and often developmental delay [23,24]. In a phase 3 trial in patients aged six and older, setmelanotide produced a mean BMI reduction of 7.9% at one year, leading to FDA approval for BBS-associated obesity in 2022 [25] – a drug developed for one class of monogenic disease proving effective in a related but genetically distinct ciliopathy. Age thresholds for setmelanotide differ between regulators: the FDA approval does not specify a lower age limit, whereas the European Medicines Agency restricts use to age six and older for POMC, PCSK1, LEPR deficiency, and BBS [12]. Setmelanotide is under investigation in acquired hypothalamic obesity (e.g., NCT04967287), with no regulatory approval yet [26].

Prader-Willi syndrome (PWS), the most common syndromic cause of childhood obesity, results from loss of expression of paternally inherited genes at chromosome 15q11-q13 – a large deletion in roughly 60% of cases, maternal uniparental disomy in about 35%, and an imprinting-center defect in the remainder [27]. Unlike the leptin-melanocortin disorders and ciliopathies, PWS begins with hypotonia and feeding difficulty in infancy, reversing into pronounced hyperphagia in early childhood – a biphasic course that is itself diagnostic [28]. Alström syndrome, caused by biallelic ALMS1 mutations, is another ciliopathy that converges on childhood obesity but adds cone-rod retinal dystrophy, sensorineural hearing loss, and dilated cardiomyopathy that can be fatal if unrecognized [29].

2.6 Deciding whom to test

Because these disorders are individually rare but collectively account for a meaningful share of severe pediatric obesity, guidelines favor a pragmatic threshold over testing every child with a high BMI. The Endocrine Society recommends testing when obesity begins before age five with extreme hyperphagia or a family history of extreme obesity [30]. Recent cohort work has sharpened this: an onset age below 3.9 years gives the best sensitivity-specificity combination for monogenic obesity, and a BMI at age two of at least 24 kg/m² has been proposed as a screening threshold for infants under five [31]. Services applying these criteria report high diagnostic yield: in one UK cohort using the national genomic panel, most tested children had onset before five years and hyperphagia, and microarray testing increased yield further in those with coexisting developmental delay [32]. NGS panels covering the leptin-melanocortin and major syndromic genes have effectively replaced sequential single-gene testing [32]. Figure 3 summarizes this decision pathway: onset before four years with persistent hyperphagia triggers an NGS obesity gene panel; coexisting dysmorphism or developmental delay adds chromosomal microarray; and children without these red-flag features are better served by polygenic risk consideration and standard lifestyle management than by broad genetic testing. The resulting diagnostic yield across cohorts is summarized in Box 1.

Box 1. Cohort synthesis (frequency of monogenic obesity): Across cohorts applying Endocrine Society-consistent criteria, monogenic and syndromic causes are identified in roughly 2-5% of unselected children with severe obesity, rising to 10-15% with onset before age three and pronounced hyperphagia [18,19,32]. This gradient justifies phenotype-triggered rather than universal testing.




Figure 1. Three-tier genetic architecture of childhood obesity and its clinical translation. The model integrates monogenic, polygenic, and epigenetic contributions within a shared leptin-melanocortin signalling pathway, and links each tier to a corresponding clinical action: diagnosis, risk stratification, and intervention.

Table 1. Principal monogenic and syndromic genetic causes of childhood obesity.

Gene Syndrome /	Pathway step affected	Distinguishing clinical features	Approx. prevalence in severe pediatric obesity	Targeted therapy
LEP	Leptin (ligand)	Undetectable leptin; hyperphagia from infancy; hypogonadism; recurrent infection	Very rare; consanguineous pedigrees	Metreleptin
LEPR	Leptin receptor	Similar to LEP deficiency but with normal/elevated leptin	Very rare	Setmelanotide (not metreleptin)
POMC	ACTH/ α -MSH precursor	Adrenal insufficiency; red hair, pale skin (variable); neonatal hypoglycemia	Very rare	Hydrocortisone (life-saving) + setmelanotide
PCSK1	Prohormone convertase 1	Malabsorptive diarrhea; ACTH deficiency; hypogonadotropic hypogonadism	Very rare	Setmelanotide
MC4R	Melanocortin-4 receptor	Milder hyperphagia; autosomal dominant; incomplete penetrance	1.5-5.8% (most common monogenic cause)	Not an approved setmelanotide indication; largely supportive
Bardet-Biedl syndrome	BBSome / ciliary transport	Retinal dystrophy, polydactyly, renal anomalies, developmental delay	Rare (ciliopathy)	Setmelanotide (FDA-approved 2022)
Prader-Willi syndrome	15q11-q13 imprinting	Infantile hypotonia $\rightarrow$ childhood hyperphagia; intellectual disability	Most common syndromic cause	No approved targeted drug; multidisciplinary management
Alström syndrome	ALMS1 / ciliary function	Cone-rod dystrophy, hearing loss, dilated cardiomyopathy	Very rare (ciliopathy)	Supportive; not currently setmelanotide-approved

3. The Polygenic Architecture of Childhood Obesity

3.1 From candidate loci to genome-wide discovery

Where monogenic obesity is defined by rare variants of large effect, the polygenic architecture is the opposite: common variants, individually of small effect, that in aggregate account for a substantial share of population-level BMI variation. The locus first identified by genome-wide association, and still the most extensively replicated, lies in the first intron of *FTO*; the risk allele is associated with higher BMI, increased energy intake, and a preference for energy-dense foods, and meta-analyses across ancestries have confirmed the association in children and adolescents, with pooled odds ratios around 1.35 per risk allele [33,34]. A locus near *MC4R*, distinct from the coding mutations described above, shows a more equivocal pattern: a systematic review and meta-analysis of the rs17782313 variant found a modest association with appetite (OR 1.25, 95% CI 1.01-1.49) that was significant only under a fixed-effects model and not a random-effects model, and found no significant association with energy intake overall, underscoring that common-variant appetite effects are considerably subtler and less consistent than monogenic hyperphagia [35]. Individual pediatric cohort studies have nonetheless reported associations between the same variant and greater food-enjoyment or eating in the absence of hunger [36]. A third locus, *ADCY3*, was identified through GWAS and subsequently shown to colocalize with *MC4R* at neuronal primary cilia, the same organelle disrupted in Bardet-Biedl and Alström syndromes, linking the common-variant and ciliopathy branches of obesity genetics [21].

Large-scale meta-analyses restricted to children, rather than adults, have identified dozens of genome-wide significant loci: an early meta-analysis of more than 61,000 children aged 2-10 years found twenty-five independent loci [37], and a subsequent trans-ancestry analysis expanded this to thirty-nine loci while demonstrating that childhood BMI genetic architecture is not simply a smaller version of adult obesity genetics – some loci show age-specific effects, prominent in childhood but not adulthood, or vice versa [38]. This matters clinically: a polygenic score built from adult GWAS data does not automatically transfer with equal accuracy to a five-year-old, and recent methodological effort has focused on correcting for that mismatch.

3.2 Polygenic risk scores: from association to prediction

The clinical translation of GWAS findings is the polygenic risk score (PRS), a weighted sum of risk-allele dosages across the genome. The most consequential recent advance came from a multi-ancestry effort drawing on genetic data from more than five million individuals, which produced a score explaining 17.6% of BMI variance among adult European-ancestry participants in the UK Biobank – roughly double the 8.5% achieved by the previous best-performing score [39]. This adult figure should not be read as the pediatric performance of the same score; rather, its value in children lies in longitudinal prediction. In the Avon Longitudinal Study of Parents and Children (ALSPAC), children with higher polygenic scores showed accelerated BMI gain beginning as early as 2.5 years of age and an earlier adiposity rebound – the point in early childhood, normally around age five to six, when BMI begins rising again after its post-infancy decline, itself a long-recognized predictor of later obesity [39]. Figure 2 summarizes these findings: Panel A shows the ancestry gap in adult variance explained, and Panel B shows that adding the score to predictors available at birth nearly doubled the variance in BMI explained at age eight, from 11% to 21%, while adding it to a child's own BMI measured at age five improved prediction of BMI at age eighteen from 22% to 35% [39]. The same study found that individuals with higher polygenic scores lost slightly more weight in year one of intensive intervention (0.55 kg per SD) but regained more afterward, suggesting polygenic risk shapes both weight gain and maintenance [39].

Performance is also markedly uneven across ancestries: the same multi-ancestry score explained 16% of variance in East Asian-American participants but only 2.2% in a cohort of rural Ugandans [39] – consistent with a broader literature showing that scores derived predominantly from European-ancestry GWAS lose much of their predictive power outside that population [40]. Near-term clinical application of pediatric PRS therefore needs either ancestry-matched training data or an explicit acknowledgment that the tool will underperform for a large share of the world's children.




Figure 2. Contribution of polygenic risk scores (PRS) to BMI prediction across ancestries and across age. Panel A: variance in adult BMI explained by the multi-ancestry PRS across selected populations. Panel B: incremental variance in childhood/adolescent BMI explained when the PRS is added to birth-available predictors (age 8) or to early-life BMI (age 18). Data from Smit et al., *Nature Medicine*, 2025 [39].

3.3 Gene-environment interaction

The polygenic signal is modulated by the same lifestyle factors that shape common obesity generally. Physical activity attenuates the effect of FTO variants on obesity risk, replicated in a meta-analysis of more than 218,000 adults and 19,000 children [41]. Dietary fiber intake shows a comparable, if less consistently replicated, interaction: the association between FTO risk alleles and adiposity was strongest among individuals with low fiber intake and attenuated at higher intake [42]. The FTO and MC4R loci also do not act independently: in a joint analysis of Finnish adolescents and French adults, carrying three or four combined risk alleles conferred roughly a three-fold increased childhood obesity risk, versus a more modest 1.8-fold increase for adults – an age-dependent interaction echoing the broader finding that childhood polygenic risk behaves differently from adult risk [43]. The trajectory data linking polygenic scores to BMI across childhood are synthesized in Box 2.

Box 2. Cohort synthesis (polygenic risk score and BMI trajectory): ALSPAC data place the earliest detectable effect of high polygenic risk at 2.5 years, as accelerated weight gain and premature adiposity rebound; by age eight, adding the score to birth-available predictors nearly doubles explained BMI variance, and by age eighteen combining an age-five BMI measurement with the score explains over a third of variance [39]. This opens a narrow but real window: identifying high-risk children before conventional risk factors have had time to act.

4. Epigenetic Programming: The Missing Link Between Genome and Environment

4.1 The developmental-origins framework

Neither monogenic mutations nor an inherited polygenic score can fully account for the observation that a child's obesity risk is shaped by conditions in utero, independent of inherited sequence. The developmental origins of health and disease (DOHaD) framework, extending Barker's original observations linking fetal undernutrition to adult cardiometabolic disease, proposes that the intrauterine environment (maternal adiposity, hyperglycemia, and inflammation) leaves lasting biological marks on the fetus, with epigenetic modification, chiefly DNA methylation, as the leading candidate mechanism [44,45].

4.2 Cord-blood methylation as a mediator

The most detailed test of this hypothesis comes from the Boston Birth Cohort, a predominantly Black, low-income, urban cohort in which 903 mother-child pairs were followed from birth to age eighteen. An epigenome-wide association study of cord-blood DNA identified 481 CpG sites associated with maternal pre-pregnancy BMI; of these, 123 were themselves associated with childhood overweight or obesity, with effect sizes ranging from a 42% decrease to an 87% increase in risk per standard-deviation change in methylation [46]. Formal mediation analysis identified fourteen CpG sites through which the maternal BMI-childhood obesity association was statistically mediated, with individual mediated proportions from about 4% to just over 25% [46]. The implicated genes include AKAP7 (energy metabolism) and CAMK2B (previously linked to adult metabolic syndrome), lending the association biological plausibility [46]. A separate cohort using an independent methylation risk score found that cord-blood methylation partially mediated the effect of pre-pregnancy BMI on BMI z-score as early as age three, suggesting the epigenetic signal is detectable well before school entry [47]. The mediation analysis from the Boston Birth Cohort is quantified in Box 3.

4.3 A candidate mechanistic route: maternal inflammation and the kynurenine pathway

One proposed route linking maternal physiology to fetal epigenetic change runs through inflammation. Maternal obesity, gestational diabetes, and hypertensive disorders of pregnancy are associated with low-grade systemic inflammation, and emerging work implicates the kynurenine pathway – the principal route of tryptophan catabolism, activated by inflammatory signalling – as an intermediary [45]. Under this model, maternal inflammation drives epigenetically mediated changes in kynurenine-pathway gene expression, and its metabolites have immunoregulatory properties that could feed back on placental and fetal immune programming [45]. The pathway remains a hypothesis under investigation, but it offers a mechanistically coherent bridge between an epidemiological association, maternal obesity predicts offspring obesity, and a testable, modifiable biological intermediate.

4.4 Reversibility

If epigenetic programming were fixed at birth, it would be a marker of risk but not a target for intervention. Evidence suggests otherwise, at least for adult blood DNA methylation: bariatric surgery identified 41 differentially methylated positions associated with weight loss, with SMAD6 and PFKFB3 strongest, and five top CpG sites replicated in BMI-discordant monozygotic twins [48]. The same analysis found bariatric surgery decelerated epigenetic age, a methylation-based estimate of biological age, by an average of more than four years within twelve months [48], indicating obesity-associated epigenetic changes are not permanent. A separate meta-analysis of post-bariatric methylation studies also reported hypomethylation, and presumed increased expression, of LEP and POMC after surgery, offering a plausible mechanistic bridge back to the leptin-melanocortin pathway discussed in Section 2. Whether comparable reversibility extends to intrauterine programming captured in cord blood, and whether maternal metabolic optimization before or during pregnancy can shift the epigenetic profile transmitted to a child, remains an open, clinically important question.

Box 3. Cohort synthesis (Boston Birth Cohort methylation mediation): In 903 mother-child pairs followed to age eighteen, maternal pre-pregnancy BMI was linked to methylation at 481 cord-blood CpG sites; 123 predicted childhood overweight or obesity, and fourteen formally mediated the maternal BMI-child obesity association, with mediated proportions of 4-25% [46]. These figures quantify how much of the maternal-to-child obesity transmission plausibly runs through a measurable epigenetic route rather than inherited sequence or postnatal environment alone.

5. Pharmacogenetics and Personalized Therapy

5.1 Matching drug to mechanism

The clearest example of genotype-guided therapy in pediatric obesity is the leptin-melanocortin pathway itself. Metreleptin is specific to leptin deficiency and is pharmacologically irrelevant in other genetic obesity, since it supplies a hormone that downstream disorders do not lack [10,12]. Setmelanotide, conversely, was designed to re-engage the melanocortin-4 receptor itself, and phase 3 trials have demonstrated efficacy across LEPR, POMC, and PCSK1 deficiency, disorders upstream of MC4R, and separately in BBS [12,25]. Notably, MC4R deficiency itself is not an approved setmelanotide indication, since a mutated receptor may not respond reliably to its own agonist; management there remains largely supportive [12,18]. In a phase 2 trial in acquired hypothalamic obesity, setmelanotide reduced hunger and BMI [26]. Liraglutide, a GLP-1 receptor agonist, is approved for adolescents ≥ 12 years and, more recently, children ≥ 6 with non-syndromic obesity, producing greater BMI reduction than

placebo [49,50]. It is reserved for polygenic obesity after monogenic and syndromic causes are excluded; it is not an alternative to setmelanotide where a leptin-melanocortin diagnosis is confirmed.

5.2 Genetic and biochemical predictors of response to lifestyle intervention

Outside a specific molecular diagnosis, genetic variation also modulates response to standard behavioral weight-management programs, though effects are more modest than the monogenic story suggests. In Look AHEAD, each copy of the FTO risk allele (rs3751812) predicted 1.56 kg more weight regain among participants assigned to standard diabetes-support-and-education ($P=0.005$), an effect not seen among those assigned to intensive lifestyle intervention ($P=0.761$), suggesting intensive programs may partly overcome an unfavorable genotype [51,52]. Baseline leptin shows a comparable, if more modest, pediatric pattern: in a cohort of 248 children in the year-long "Obeldicks" lifestyle intervention, higher baseline leptin was significantly, if weakly, correlated with smaller reductions in BMI-SDS ($r = -0.27$), waist circumference ($r = -0.64$), and body fat ($r = -0.26$) in multivariate models adjusted for age, BMI, sex, and pubertal stage, consistent with leptin resistance blunting response [53]; a separate cohort found baseline BMI a stronger predictor than leptin itself [54]. These markers help explain heterogeneity in response after the fact but are not yet precise enough to guide an individual child's treatment choice in advance. The genetic predictors of treatment response across major trials are summarized in Box 4.

5.3 Toward integrated, precision-guided care

The practical trajectory is toward integrating these layers rather than treating them as competing frameworks. A polygenic score is most useful in a child without a high-penetrance mutation; conversely, in a child with a confirmed pathogenic MC4R or POMC variant, the polygenic background still matters, since it appears to modulate whether carriers present with normal weight, overweight, or severe obesity [6]. Emerging tools are also lowering the barrier to diagnosing resembling syndromic causes: long-read nanopore sequencing can now resolve methylation status at the SNRPN locus directly, distinguishing the deletion, uniparental-disomy, and imprinting-defect subtypes of Prader-Willi syndrome in a single assay [55]. As these technologies become more accessible, the rate-limiting step is likely to shift from testing availability to clinician recognition of which children should be tested.

Box 4. Cohort synthesis (genetic predictors of treatment response): Across the Look AHEAD and Diabetes Prevention Program trials, the FTO risk allele was associated with greater weight regain specifically under lower-intensity behavioral support, an effect not seen under intensive lifestyle intervention [51,52]. In pediatric lifestyle-intervention cohorts, higher baseline leptin has repeatedly, though not universally, predicted a smaller magnitude of weight loss, consistent with leptin resistance blunting the physiological response to caloric restriction [53,54].




Figure 3. Diagnostic algorithm for suspected genetic obesity. A phenotype-triggered pathway: onset before four years with persistent hyperphagia prompts an NGS obesity gene panel; coexisting dysmorphism or developmental delay adds chromosomal microarray testing; children lacking these red-flag features are more appropriately managed with polygenic risk consideration and standard lifestyle care.

Table 2. Pharmacological agents used in genetically defined and common pediatric obesity.

Agent	Molecular target	Principal indication	Reported effect
Metreleptin	Leptin replacement	Congenital leptin (LEP) deficiency	Marked reduction in hyperphagia and body fat; restores pubertal development
Setmelanotide	MC4R agonist	LEPR, POMC, PCSK1 deficiency; Bardet-Biedl syndrome	Clinically significant reduction in hunger and BMI in phase 3 trials
Liraglutide	GLP-1 receptor agonist	Non-syndromic pediatric obesity (age ≥ 6 , or ≥ 12 for the original approval)	Greater BMI reduction than placebo in randomized trials

6. LIMITATIONS

Several limitations should be acknowledged. Most GWAS and polygenic-score data derive from European-ancestry populations, limiting generalizability and cutting predictive performance by an order of magnitude in some non-European cohorts [39,40]. Epigenetic studies here are predominantly cross-sectional or single-cohort, and causality between maternal methylation and childhood obesity remains unproven. Pediatric pharmacogenetic data are sparse: most obesity drug trials are powered for overall efficacy, not genotype-stratified response, so treatment-response findings are largely extrapolated from adult trials. Gene-environment interaction data also come overwhelmingly from Western, high-income settings; how these interactions play out elsewhere is largely unknown. Finally, the evidence base is subject to publication bias: positive findings are more likely to be published than negative or null results, particularly in pharmacogenetic and epigenetic studies, which may inflate the apparent strength of some associations discussed here.

CONCLUSION AND FUTURE DIRECTIONS

Childhood obesity genetics is best understood not as a search for “the” obesity gene but as a layered system: rare, high-penetrance mutations that produce a recognizable clinical syndrome and now have a matched pharmacological antidote in most cases; a common-variant polygenic background, increasingly measurable as a single score, that shapes population-wide risk and is detectable from early childhood; and an epigenetic layer, written before birth, that connects maternal metabolic health to offspring risk through a mechanism, cord-blood DNA methylation, that is at least partially reversible later in life. None of the three tiers alone explains the full clinical picture, and the more interesting recent findings sit at their intersections: polygenic background modulating monogenic penetrance, ciliopathy genes shared between rare syndromes and common GWAS loci, and lifestyle-intervention outcomes that depend on both genotype and program intensity.

Several priorities follow. Polygenic risk scores require validation and re-derivation in non-European populations before responsible deployment outside their original cohorts [39,40]. NGS panels for the leptin-melanocortin and ciliopathy genes should be integrated into routine pediatric pathways wherever onset occurs before roughly four years with hyperphagia, since diagnostic yield justifies the cost and a genetic diagnosis directly changes treatment [30,31,32]. The reversibility of epigenetic marks after bariatric surgery raises an unanswered question (whether maternal metabolic optimization before or during pregnancy can shift the signature transmitted to a child) requiring dedicated intervention trials. Trials stratified prospectively by genetic risk, rather than genotyped retrospectively, are needed to establish whether early identification of high-risk children improves outcomes when paired with earlier intervention. A plausible decade-long trajectory is that ancestry-matched polygenic scores enter routine screening, NGS panels become first-line for early-onset hyperphagic obesity, and cord-blood markers move toward risk-stratification tools – though each step depends on trial evidence that does not yet exist.

Genetics is not deterministic. A polygenic score explaining a fifth to a third of BMI variance leaves most variance to environment, behavior, and chance; even severe monogenic disorders now have matched therapies that substantially normalize weight. Genetic evaluation offers not a verdict but a map – which children benefit most from early attention, and for a minority, a molecular diagnosis that changes what “treatment” means. For the practicing pediatrician: any child with obesity onset before age four and persistent hyperphagia should be considered for NGS-based genetic testing.

ACKNOWLEDGMENTS: The authors express their gratitude to their colleagues for the useful discussions and critical comments that helped improve the quality of this review.

Authors' contribution: All authors contributed equally to the conception, design, literature review, data analysis, manuscript drafting, and final approval of the version to be published.

Conflict of interest: The authors declare no conflict of interest.

Financial support: This research received no specific grant from any funding agency in the public, commercial, or non-profit sectors.

Ethics statement: As this article is a narrative literature review and does not involve original data collection from human participants or animals, ethical approval was not required. All cited studies were conducted in accordance with their respective ethical standards and the principles of the Declaration of Helsinki.

REFERENCES

1. Gao L, Peng W, Xue H, Wu Y, Zhou H, Jia P, Wang Y. Spatial-temporal trends in global childhood overweight and obesity from 1975 to 2030: a weight mean center and projection analysis of 191 countries. *Global Health*. 2023 Aug 4;19(1):53. doi: 10.1186/s12992-023-00954-5.
2. Khusainova R, Minniakhmetov I, Vasyukova O, Yalaev B, Salakhov R, Kopytina D, Guseinova R, Dobrev E, Melnichenko G, Dedov I, Mokrysheva N. Genetic Landscape of Obesity in Children: Research Advances and Prospects. *J Obes*. 2025 Jul 11;2025:9186826. doi: 10.1155/job/9186826.
3. GBD 2021 Adolescent BMI Collaborators. Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. *Lancet*. 2025 Mar 8;405(10481):785-812. doi: 10.1016/S0140-6736(25)00397-6.
4. Chamarithi VS, Daley SF. Genetic and Syndromic Causes of Obesity: Diagnosis and Management. 2025 Sep 15. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-.
5. Herrera BM, Keildson S, Lindgren CM. Genetics and epigenetics of obesity. *Maturitas*. 2011 May;69(1):41-9. doi: 10.1016/j.maturitas.2011.02.018.
6. Chami N, Preuss M, Walker RW, Moscati A, Loos RJF. The role of polygenic susceptibility to obesity among carriers of pathogenic mutations in MC4R in the UK Biobank population. *PLoS Med*. 2020 Jul 21;17(7):e1003196. doi: 10.1371/journal.pmed.1003196.
7. Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, Sewter CP, Digby JE, Mohammed SN, Hurst JA, Cheetham CH, Earley AR, Barnett AH, Prins JB, O'Rahilly S. Congenital leptin deficiency is associated with severe early-onset obesity in humans. *Nature*. 1997 Jun 26;387(6636):903-8. doi: 10.1038/43185.
8. Saeed S, Khanam R, Janjua QM, Manzoor J, Ning L, Hanook S, Canouil M, Ali M, Ayesha H, Khan WI, Farooqi IS, Yeo GSH, O'Rahilly S, Bonnefond A, Butt TA, Arslan M, Froguel P. High morbidity and mortality in children with untreated congenital deficiency of leptin or its receptor. *Cell Rep Med*. 2023 Sep 19;4(9):101187. doi: 10.1016/j.xcrm.2023.101187.
9. Clément K, Vaisse C, Lahlou N, Cabrol S, Pelloux V, Cassuto D, Gourmelen M, Dina C, Chambaz J, Lacorte JM, Basdevant A, Bougnères P, Lebouc Y, Froguel P, Guy-Grand B. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. *Nature*. 1998 Mar 26;392(6674):398-401. doi: 10.1038/32911.
10. Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O'Rahilly S. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. *N Engl J Med*. 1999 Sep 16;341(12):879-84. doi: 10.1056/NEJM199909163411204.
11. Yupanqui-Lozano H, Huertas-Quintero JA, Yupanqui-Velazco ME, Salinas-Osornio RA, Restrepo CM, Gonzalez A, Nava-Gonzalez EJ, Celis-Regalado LG, Neri Morales C, Hernandez-Escalante VM, Licinio J, Laviada-Molina HA, Rodriguez-Ayala E, Arango C, Bastarrachea RA. One-year metreleptin in Colombian sisters with congenital leptin deficiency. *Adipocyte*. 2025 Dec;14(1):2508188. doi: 10.1080/21623945.2025.2508188.
12. Clément K, van den Akker E, Argente J, Bahm A, Chung WK, Connors H, De Waele K, Farooqi IS, Gonneau-Lejeune J, Gordon G, Kohlsdorf K, Poitou C, Puder L, Swain J, Stewart M, Yuan G, Wabitsch M, Kühnen P; Setmelanotide POMC and LEPR Phase 3 Trial Investigators. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. *Lancet Diabetes Endocrinol*. 2020 Dec;8(12):960-970. doi: 10.1016/S2213-8587(20)30364-8.
13. Krude H, Biebermann H, Luck W, Horn R, Brabant G, Grüters A. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. *Nat Genet*. 1998 Jun;19(2):155-7. doi: 10.1038/509.
14. Mendiratta MS, Yang Y, Balazs AE, Willis AS, Eng CM, Karaviti LP, Potocki L. Early onset obesity and adrenal insufficiency associated with a homozygous POMC mutation. *Int J Pediatr Endocrinol*. 2011;2011(1):5. doi: 10.1186/1687-9856-2011-5.
15. Lewis A, Thant AA, Aslam A, Aung PPM, Azmi S. Diagnosis and management of adrenal insufficiency. *Clin Med (Lond)*. 2023 Mar;23(2):115-118. doi: 10.7861/clinmed.2023-0067.
16. Jackson RS, Creemers JW, Ohagi S, Raffin-Sanson ML, Sanders L, Montague CT, Hutton JC, O'Rahilly S. Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. *Nat Genet*. 1997 Jul;16(3):303-6. doi: 10.1038/ng0797-303.
17. Buonocore F, McGlacken-Byrne SM, Del Valle I, Achermann JC. Current Insights Into Adrenal Insufficiency in the Newborn and Young Infant. *Front Pediatr*. 2020 Dec 14;8:619041. doi: 10.3389/fped.2020.619041.
18. Farooqi IS, Keogh JM, Yeo GS, Lank EJ, Cheetham T, O'Rahilly S. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. *N Engl J Med*. 2003 Mar 20;348(12):1085-95. doi: 10.1056/NEJMoa022050.
19. De Rosa MC, Chesi A, McCormack S, Zhou J, Weaver B, McDonald M, Christensen S, Liimatta K, Rosenbaum M, Hakonarson H, Doege CA, Grant SFA, Hirschhorn JN, Thaker VV. Characterization of Rare Variants in MC4R in African American and Latino Children With Severe Early-Onset Obesity. *J Clin Endocrinol Metab*. 2019 Jul 1;104(7):2961-2970. doi: 10.1210/je.2018-02657.

20. Zorn S, Bounds R, Williamson A, Lawler K, Hanssen R, Keogh J, Henning E, Smith M, Fielding BA, Umpleby AM, Yasmeen S, Marti-Solano M, Langenberg C, Wabitsch M, Collet TH, Farooqi IS. Obesity due to MC4R deficiency is associated with reduced cholesterol, triglycerides and cardiovascular disease risk. *Nat Med*. 2025 Dec;31(12):4180-4188. doi: 10.1038/s41591-025-03976-1.
21. Siljee JE, Wang Y, Bernard AA, Ersoy BA, Zhang S, Marley A, Von Zastrow M, Reiter JF, Vaisse C. Subcellular localization of MC4R with ADCY3 at neuronal primary cilia underlies a common pathway for genetic predisposition to obesity. *Nat Genet*. 2018 Feb;50(2):180-185. doi: 10.1038/s41588-017-0020-9.
22. Collet TH, Dubern B, Mokrosinski J, Connors H, Keogh JM, Mendes de Oliveira E, Henning E, Poitou-Bernert C, Oppert JM, Tounian P, Marchelli F, Alili R, Le Beyec J, Pépin D, Lacorte JM, Gottesdiener A, Bounds R, Sharma S, Folster C, Henderson B, O'Rahilly S, Stoner E, Gottesdiener K, Panaro BL, Cone RD, Clément K, Farooqi IS, Van der Ploeg LHT. Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency. *Mol Metab*. 2017 Oct;6(10):1321-1329. doi: 10.1016/j.molmet.2017.06.015.
23. Forsythe E, Beales PL. Bardet-Biedl syndrome. *Eur J Hum Genet*. 2013 Jan;21(1):8-13. doi: 10.1038/ejhg.2012.115.
24. Sridhar S, Palanivel S, Senthilkumar J, Kavitha K, Geethaanjali V, Vasanthiy N, Dharmaraj C. Clinical Presentation and Co-Morbidities in Bardet-Biedel Syndrome: Case Series from a Single Centre. *Indian J Endocrinol Metab*. 2025 Jan-Feb;29(1):89-94. doi: 10.4103/ijem.ijem_278_24.
25. Haqq AM, Chung WK, Dollfus H, Haws RM, Martos-Moreno GÁ, Poitou C, Yanovski JA, Mittleman RS, Yuan G, Forsythe E, Clément K, Argente J. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period. *Lancet Diabetes Endocrinol*. 2022 Dec;10(12):859-868. doi: 10.1016/S2213-8587(22)00277-7. Epub 2022 Nov 7. Erratum in: *Lancet Diabetes Endocrinol*. 2023 Feb;11(2):e2. doi: 10.1016/S2213-8587(22)00360-6.
26. Roth CL, Scimia C, Shoemaker AH, Gottschalk M, Miller J, Yuan G, Malhotra S, Abuzzahab MJ. Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial. *Lancet Diabetes Endocrinol*. 2024 Jun;12(6):380-389. doi: 10.1016/S2213-8587(24)00087-1.
27. Madeo SF, Zagaroli L, Vandelli S, Calcaterra V, Crinò A, De Sanctis L, Faienza MF, Fintini D, Guazzarotti L, Licenziati MR, Mozzillo E, Pajno R, Scarano E, Street ME, Wasniewska M, Bocchini S, Bucolo C, Buganza R, Chiarito M, Corica D, Di Candia F, Francavilla R, Fratangeli N, Improda N, Morabito LA, Mozzato C, Rossi V, Schiavariello C, Farello G, Iughetti L, Salpietro V, Salvatoni A, Giordano M, Grugni G, Delvecchio M. Endocrine features of Prader-Willi syndrome: a narrative review focusing on genotype-phenotype correlation. *Front Endocrinol (Lausanne)*. 2024 Apr 26;15:1382583. doi: 10.3389/fendo.2024.1382583.
28. Tauber M, Diene G, Mimoun E, Çabal-Berthoumieu S, Mantoulan C, Molinas C, Muscatelli F, Salles JP. Prader-Willi syndrome as a model of human hyperphagia. *Front Horm Res*. 2014;42:93-106. doi: 10.1159/000358317.
29. Marshall JD, Maffei P, Collin GB, Naggert JK. Alström syndrome: genetics and clinical overview. *Curr Genomics*. 2011 May;12(3):225-35. doi: 10.2174/138920211795677912.
30. Styne DM, Arslanian SA, Connor EL, Farooqi IS, Murad MH, Silverstein JH, Yanovski JA. Pediatric Obesity-Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2017 Mar 1;102(3):709-757. doi: 10.1210/jc.2016-2573.
31. Zorn S, de Groot CJ, Brandt-Heunemann S, von Schnurbein J, Abawi O, Bounds R, Ruck L, Guijo B, Martos-Moreno GÁ, Nicaise C, Courbage S, Klehr-Martinelli M, Siebert R, Dubern B, Poitou C, Clément K, Argente J, Kühnen P, Farooqi IS, Wabitsch M, van den Akker E. Early childhood height, weight, and BMI development in children with monogenic obesity: a European multicentre, retrospective, observational study. *Lancet Child Adolesc Health*. 2025 May;9(5):297-305. doi: 10.1016/S2352-4642(25)00065-3. Erratum in: *Lancet Child Adolesc Health*. 2025 Jun;9(6):e14. doi: 10.1016/S2352-4642(25)00128-2.
32. Harvengt J, Hannon M, Palmeira L, Lebrethon MC, Dideberg V, Bours V. Monogenic etiologies in a cohort of early onset obesity: a real-world experience from Belgium. *Front Endocrinol (Lausanne)*. 2025 Aug 1;16:1608398. doi: 10.3389/fendo.2025.1608398.
33. Lan N, Lu Y, Zhang Y, Pu S, Xi H, Nie X, Liu J, Yuan W. FTO - A Common Genetic Basis for Obesity and Cancer. *Front Genet*. 2020 Nov 16;11:559138. doi: 10.3389/fgene.2020.559138.
34. Liu C, Mou S, Cai Y. FTO gene variant and risk of overweight and obesity among children and adolescents: a systematic review and meta-analysis. *PLoS One*. 2013 Nov 22;8(11):e82133. doi: 10.1371/journal.pone.0082133.
35. Álvarez-Martín C, Caballero FF, de la Iglesia R, Alonso-Aperte E. Association of MC4R rs17782313 Genotype With Energy Intake and Appetite: A Systematic Review and Meta-analysis. *Nutr Rev*. 2025 Mar 1;83(3):e931-e946. doi: 10.1093/nutrit/nuae075.
36. Ho-Urriola J, Guzmán-Guzmán IP, Smalley SV, González A, Weisstaub G, Domínguez-Vásquez P, Valladares M, Amador P, Hodgson MI, Obregón AM, Santos JL. Melanocortin-4 receptor polymorphism rs17782313: association with obesity and eating in the absence of hunger in Chilean children. *Nutrition*. 2014 Feb;30(2):145-9. doi: 10.1016/j.nut.2013.05.030

37. Vogelesang S, Bradfield JP, Ahluwalia TS, Curtin JA, et al. Novel loci for childhood body mass index and shared heritability with adult cardiometabolic traits. *PLoS Genet.* 2020 Oct 12;16(10):e1008718. doi: 10.1371/journal.pgen.1008718.
38. Downie CG, Shrestha P, Okello S, Yaser M et al. Trans-ancestry genome-wide association study of childhood body mass index identifies novel loci and age-specific effects. *HGG Adv.* 2025 Apr 10;6(2):100411. doi: 10.1016/j.xhgg.2025.100411.
39. Smit RAJ, Wade KH, Hui Q, Arias JD et al. Polygenic prediction of body mass index and obesity through the life course and across ancestries. *Nat Med.* 2025 Sep;31(9):3151-3168. doi: 10.1038/s41591-025-03827-z.
40. Martin AR, Kanai M, Kamatani Y, Okada Y, Neale BM, Daly MJ. Clinical use of current polygenic risk scores may exacerbate health disparities. *Nat Genet.* 2019 Apr;51(4):584-591. doi: 10.1038/s41588-019-0379-x. Epub 2019 Mar 29. Erratum in: *Nat Genet.* 2021 May;53(5):763. doi: 10.1038/s41588-021-00797-z.
41. Kilpeläinen TO, Qi L, Brage S, Sharp SJ, Sonestedt E et al. Physical activity attenuates the influence of FTO variants on obesity risk: a meta-analysis of 218,166 adults and 19,268 children. *PLoS Med.* 2011 Nov;8(11):e1001116. doi: 10.1371/journal.pmed.1001116.
42. Hosseini-Esfahani F, Koochakpoor G, Daneshpour MS, Mirmiran P, Sedaghati-Khayat B, Azizi F. The interaction of fat mass and obesity associated gene polymorphisms and dietary fiber intake in relation to obesity phenotypes. *Sci Rep.* 2017 Dec 22;7(1):18057. doi: 10.1038/s41598-017-18386-8.
43. Cauchi S, Stutzmann F, Cavalcanti-Proença C, Durand E, Pouta A, Hartikainen AL, Marre M, Vol S, Tammelin T, Laitinen J, Gonzalez-Izquierdo A, Blakemore AI, Elliott P, Meyre D, Balkau B, Järvelin MR, Froguel P. Combined effects of MC4R and FTO common genetic variants on obesity in European general populations. *J Mol Med (Berl).* 2009 May;87(5):537-46. doi: 10.1007/s00109-009-0451-6.
44. Barker DJ. The developmental origins of adult disease. *J Am Coll Nutr.* 2004 Dec;23(6 Suppl):588S-595S. doi: 10.1080/07315724.2004.10719428.
45. Gharipour M, Craig JM, Stephenson G. Epigenetic programming of obesity in early life through modulation of the kynurenine pathway. *Int J Obes (Lond).* 2025 Jan;49(1):49-53. doi: 10.1038/s41366-024-01647-8.
46. Si J, Meir AY, Hong X, Wang G, Huang W, Pearson C, Adams WG, Wang X, Liang L. Maternal pre-pregnancy BMI, offspring epigenome-wide DNA methylation, and childhood obesity: findings from the Boston Birth Cohort. *BMC Med.* 2023 Aug 23;21(1):317. doi: 10.1186/s12916-023-03003-5.
47. Chang R, Zhang Y, Sun J, Xu K, Li C, Zhang J, Mei W, Zhang H, Zhang J. Maternal pre-pregnancy body mass index and offspring with overweight/obesity at preschool age: The possible role of epigenome-wide DNA methylation changes in cord blood. *Pediatr Obes.* 2023 Jan;18(1):e12969. doi: 10.1111/ijpo.12969.
48. Talukdar FR, Escobar Marcillo DI, Laskar RS, Novoloaca A, Cuenin C, Sbraccia P, Nisticò L, Guglielmi V, Gheit T, Tommasino M, Dogliotti E, Fortini P, Herceg Z. Bariatric surgery-induced weight loss and associated genome-wide DNA-methylation alterations in obese individuals. *Clin Epigenetics.* 2022 Dec 18;14(1):176. doi: 10.1186/s13148-022-01401-9.
49. Carlsson Petri KC, Hale PM, Hesse D, Rathor N, Mastrandrea LD. Liraglutide pharmacokinetics and exposure-response in adolescents with obesity. *Pediatr Obes.* 2021 Oct;16(10):e12799. doi: 10.1111/ijpo.12799.
50. Fox CK, Barrientos-Pérez M, Bomberg EM, Dcruz J, Gies I, Harder-Lauridsen NM, Jalaludin MY, Sahu K, Weimers P, Zueger T, Arslanian S, SCALE Kids Trial Group. Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial. *N Engl J Med.* 2025 Feb 6;392(6):555-565. doi: 10.1056/NEJMoa2407379.
51. McCaffery JM, Papandonatos GD, Huggins GS, Peter I, Kahn SE, Knowler WC, Hudnall GE, Lipkin EW, Kitabchi AE, Wagenknecht LE, Wing RR; Genetic Subgroup of Look AHEAD; Look AHEAD Research Group. FTO predicts weight regain in the Look AHEAD clinical trial. *Int J Obes (Lond).* 2013 Dec;37(12):1545-52. doi: 10.1038/ijo.2013.54.
52. Papandonatos GD, Pan Q, Pajewski NM, Delahanty LM, Peter I, Erar B, Ahmad S, Harden M, Chen L, Fontanillas P; GIANT Consortium; Wagenknecht LE, Kahn SE, Wing RR, Jablonski KA, Huggins GS, Knowler WC, Florez JC, McCaffery JM, Franks PW; Diabetes Prevention Program and the Look AHEAD Research Groups. Genetic Predisposition to Weight Loss and Regain With Lifestyle Intervention: Analyses From the Diabetes Prevention Program and the Look AHEAD Randomized Controlled Trials. *Diabetes.* 2015 Dec;64(12):4312-21. doi: 10.2337/db15-0441.
53. Reinehr T, Kleber M, de Sousa G, Andler W. Leptin concentrations are a predictor of overweight reduction in a lifestyle intervention. *Int J Pediatr Obes.* 2009;4(4):215-23. doi: 10.3109/17477160902952464.
54. Murer SB, Knöpfli BH, Aeberli I, Jung A, Wildhaber J, Wildhaber-Brooks J, Zimmermann MB. Baseline leptin and leptin reduction predict improvements in metabolic variables and long-term fat loss in obese children and adolescents: a prospective study of an inpatient weight-loss program. *Am J Clin Nutr.* 2011 Apr;93(4):695-702. doi: 10.3945/ajcn.110.002212.
55. Yamada M, Okuno H, Okamoto N, Suzuki H, Miya F, Takenouchi T, Kosaki K. Diagnosis of Prader-Willi syndrome and Angelman syndrome by targeted nanopore long-read sequencing. *Eur J Med Genet.* 2023 Feb;66(2):104690. doi: 10.1016/j.ejmg.2022.104690.